Clinical trials: LOCALLY ADVANCED CERVICAL CANCERS
Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
To determine whether special tumor fighting cells that is taken from participants' tumors and grown in the laboratory and then given back to the participant will fight the participant's cancer when their immune system is…
- Conditions
- Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma, Metastatic Head and Neck Cancer, Locally Advanced Refractory/Recurrent Head and Neck Cancer
- Trial name
- NCT03991741
- Testing
- Autologous Tumor Infiltrating Lymphocytes, High-Dose Interleukin 2
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Gregory Daniels
Non Small Cell Lung Cancer, Cervical Cancer
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
The main goal of this study is to evaluate how safe and tolerable RNDO-564 is and to identify the best dose of RNDO-564 as a single agent and in combination with pembrolizumab.
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT07218003
- Testing
- RNDO-564, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 149 people
- Sponsor
- Rondo Therapeutics
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
RATIONALE: Radiation therapy uses high-energy x-rays and to kill tumor cells. Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or…
- Trial name
- NCT01107639
- Testing
- cetuximab, cisplatin, docetaxel
- Where
- 57 sites in Austria, France and 3 more
- Volunteers
- 297 people
- Sponsor
- Swiss Cancer Institute
Esophageal Cancer
Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy
This study is a two arm, randomized, prospective, multicenter study on the perioperative treatment of locally advanced resectable esophageal cancer with penpulimab combined with anlotinib hydrochloride and chemotherapy.
- Trial name
- EASOPCWAAC (NCT06586242)
- Testing
- Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Xijing Hospital
Hypopharyngeal Squamous Cell Carcinoma
Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
This clinical trial aims to evaluate the efficacy and safety of Becotatug Vedotin (EGFR-ADC) in combination with Pucotenlimab(Anti-PD-1 Monoclonal Antibody) as neoadjuvant therapy for patients with Resectable Locally Advanced…
- Trial name
- RESERVE-HC (NCT07665190)
- Testing
- Becotatug Vedotin and Pucotenlimab
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Locally Advanced Solid Tumor, Metastatic Cancer
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving…
- Conditions
- Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT03881488
- Testing
- CTX-471, Pembrolizumab (KEYTRUDA®)
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Compass Therapeutics
Oral Cancer
A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma
Surgical resection followed by concurrent chemoradiotherapy is considered as the standard of care for locally advanced OSCC (LAOSCC).
- Trial name
- NCT00933387
- Testing
- Cetuximab,Paclitaxel,Cisplatin
- Where
- Taiwan
- Volunteers
- 47 people
- Sponsor
- National Health Research Institutes, Taiwan
Head and Neck Neoplasms, Carcinoma, Squamous Cell
A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck
This is a Phase 2, multi-center, open label study of ARQ 501 in patients with locally advanced, recurrent or metastatic squamous cell cancer of the head and neck (SCCHN).
- Trial name
- NCT00358930
- Testing
- ARQ 501
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Squamous Cell Carcinoma of the Head and Neck, Basaloid Squamous Cell Carcinoma
Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck
The purpose of the Phase I part of this research study is to determine the safest and most effective dose of Abraxane when given in combination with carboplatin and Erbitux during radiation therapy for head and neck cancer.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Basaloid Squamous Cell Carcinoma, Undifferentiated Carcinoma, Adenosquamous Cell Carcinoma
- Trial name
- NCT00570674
- Testing
- Abraxane, Erbitux, Carboplatin
- Volunteers
- 29 people
- Sponsor
- Dana-Farber Cancer Institute
Head and Neck Cancer
Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer
The purpose of this study is to define the response and toxicities with the addition of Nimotuzumab to chemoradiation for head and neck cancer.
- Trial name
- NCT00702481
- Testing
- Nimotuzumab, Cisplatin, Radiation
- Where
- Singapore
- Volunteers
- 32 people
- Sponsor
- National Cancer Centre, Singapore
Esophageal Cancer
Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
A total of 120 patients with unresectable, locally advanced esophageal squamous cell carcinoma patients will be enrolled in this study and randomly divided into two groups.
- Trial name
- NCT07733830
- Testing
- Adebrelimab, Nab paclitaxel, Carboplatin
- Where
- 7 sites in China
- Volunteers
- 120 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Head and Neck Cancer
Chemoradiation Treatment for Head and Neck Cancer
This is a Phase II study of cetuximab, carboplatin and radiotherapy (RT) in patients with Locally Advanced Head and Neck Carcinomas (LAHNC) who are unfit for cisplatin.
- Trial name
- NCT00704639
- Testing
- Cetuximab, Carboplatin, Radiotherapy
- Where
- Australia
- Volunteers
- 60 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Locally Advanced Thoracic Middle-lower Segment Esophageal Squamous Cell Carcinoma
Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
This study aim to investigate Changes in tumor tissue and serum biomarkers before and after cetuximab combined with preoperative radiotherapy in locally advanced thoracic middle-lower segment esophageal squamous cell carcinoma.We…
- Trial name
- NCT02123381
- Testing
- preoperative radiotherapy, cetuximab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid…
- Conditions
- Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- NCT07503808
- Testing
- IDE034
- Where
- 15 sites in United States
- Volunteers
- 150 people
- Sponsor
- IDEAYA Biosciences
Locally Advanced Head and Neck Carcinoma
Pea Protein Oral Nutrition Supplement for the Reduction of Gastrostomy Tube Placement Rate in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiation Therapy
This phase II trial studies the effect of a plant-based oral nutrition supplement, Kate Farms Standard 1.4 and/or Standard 1.0. as a primary source of nutrition in reducing the gastrostomy tube placement rate in patients with…
- Trial name
- NCT05115760
- Testing
- Dietary Supplement, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Nasopharyngeal Carcinoma (NPC)
Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
To explore the efficacy and safety of reduced-dose radiotherapy combined with concurrent chemotherapy and immunotherapy in stage Ⅳa (AJCC 8th,) locally advanced nasopharyngeal carcinoma patients who are sensitive to induction…
- Trial name
- NCT07328841
- Testing
- Full course of PD-1blockades, Cisplatin-based induction chemotherapy, Standard-dose radiotherapy
- Where
- 12 sites in China
- Volunteers
- 456 people
- Sponsor
- Ming-Yuan Chen
Esophagus Cancer
Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer
In this randomized study, we plan to address the important question of optimum local treatment for patients with localized esophageal cancer.
- Trial name
- NCT00193141
- Testing
- Paclitaxel, Carboplatin, 5-Fluorouracil
- Volunteers
- 200 people
- Sponsor
- SCRI Development Innovations, LLC
Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer
This phase I trial studies the side effects of image-guided hyper-fractioned proton therapy in treating patients with head and neck cancer that has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed…
- Conditions
- Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Nasopharyngeal Squamous Cell Carcinoma
- Trial name
- NCT04870840
- Testing
- Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Cancer Stage IIIB, Treatment Outcome
Feasibility Study Of A Telephonic Questionnaire For Follow-Up Of Locally Advanced Cervical Cancer Patients
Cross-sectional Feasibility study on all consecutive patients of locally advanced cancer of the cervix or vault treated entirely at Tata Memorial Centre with curative intent radiation or chemoradiation.
- Conditions
- Cervical Cancer Stage IIIB, Treatment Outcome, Follow up, QUESTIONNAIRE
- Trial name
- NCT03477240
- Volunteers
- 300 people
- Sponsor
- Tata Memorial Hospital
Head and Neck Cancer, Head Cancer
RiMO-HNC-NEO1: Phase 2 Study of RiMO-301 and Hypofractionated Radiotherapy With Pembrolizumab for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer
The primary objective is to evaluate major pathologic response after RiMO-301 with hypofractionated radiotherapy and a PD-1 inhibitor (pembrolizumab), as assessed by clinical response rate using iRECIST criteria; determine…
- Conditions
- Head and Neck Cancer, Head Cancer, Neck Cancer
- Trial name
- RiMO-HNC-NEO1 (NCT07732634)
- Testing
- RiMO-301, Pembrolizumab, Radiation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Illinois Chicago
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.